Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Sales (2016 - 2025)

Historic Return on Sales for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 0.5%.

  • Viridian Therapeutics, Inc.\DE's Return on Sales rose 8889700.0% to 0.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.27%, marking a year-over-year increase of 8463500.0%. This contributed to the annual value of 893.87% for FY2024, which is 1367600.0% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Return on Sales stood at 0.5%, which was up 8889700.0% from 1343.13% recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Return on Sales peaked at 0.5% during Q3 2025, and registered a low of 1343.13% during Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Return on Sales value was 661.94% (recorded in 2023), while the average stood at 531.7%.
  • Its Return on Sales has fluctuated over the past 5 years, first plummeted by -6495600bps in 2023, then skyrocketed by 8889700bps in 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Return on Sales (Quarter) stood at 135.26% in 2021, then plummeted by -222bps to 436.05% in 2022, then tumbled by -113bps to 928.61% in 2023, then decreased by -19bps to 1108.1% in 2024, then soared by 100bps to 0.5% in 2025.
  • Its last three reported values are 0.5% in Q3 2025, 1343.13% for Q2 2025, and 1207.11% during Q1 2025.